11C-methionine in the diagnostics and management of
glioblastoma patients with rapid early progression:
nonrandomized, open label, prospective clinical trial (GlioMET)

J 2024

11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

LAKOMÝ, Radek; Martina LOJOVÁ; Lenka SOUČKOVÁ; Ludmila HYNKOVÁ; Kateřina POLÁCHOVÁ et. al.

Základní údaje

Originální název

11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)

Autoři

Vydání

BMC Cancer, LONDON, BMC, 2024, 1471-2407

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

GliMet

Impakt faktor

Impact factor: 3.400

Kód RIV

RIV/00216224:14110/24:00136529

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1186/s12885-024-12469-2

UT WoS

001249141700004

EID Scopus

2-s2.0-85196173477

Klíčová slova anglicky

Glioblastoma; Rapid early progression; Radiopharmaceutical; C-11-methionine; Clinical trial; Positron emission tomography; Radiotherapy

Štítky

14110131, 14110224, 14110516, 14110811, 14110812, Excelence Science, MOÚ, MU, rivok, user, článek v časopise

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 4. 2025 12:38, Mgr. Tereza Miškechová

Anotace

V originále

Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is used for radiotherapy treatment planning. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery and is called rapid early progression (REP). Radiotherapy planning is currently based on MRI for target volumes definitions in many radiotherapy facilities. However, patients with REP may benefit from targeting radiotherapy with other imaging modalities. The purpose of the presented clinical trial is to evaluate the utility of C-11-methionine in optimizing radiotherapy for glioblastoma patients with REP. Methods This study is a nonrandomized, open-label, parallel-setting, prospective, monocentric clinical trial. The main aim of this study was to refine the diagnosis in patients with GBM with REP and to optimize subsequent radiotherapy planning. Glioblastoma patients who develop REP within approximately 6 weeks after surgery will undergo C-11-methionine positron emission tomography (PET/CT) examinations. Target volumes for radiotherapy are defined using both standard planning T1-weighted contrast-enhanced MRI and PET/CT. The primary outcome is progression-free survival defined using RANO criteria and compared to a historical cohort with REP treated without PET/CT optimization of radiotherapy. Discussion PET is one of the most modern methods of molecular imaging. C-11-Methionine is an example of a radiolabelled (carbon 11) amino acid commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. Optimized radiotherapy may also have the potential to cover those regions with a high risk of subsequent progression, which would not be identified using standard-of-care MRI for radiotherapy planning. This is one of the first study focused on radiotherapy optimization for subgroup of patinets with REP.

Návaznosti

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(Kód CEP: EF16_013/0001826)

Název: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií, PO 1 Posilování kapacit pro kvalitní výzkum

90249, velká výzkumná infrastruktura

Název: CZECRIN IV

Citovat

LAKOMÝ, Radek; Martina LOJOVÁ; Lenka SOUČKOVÁ; Ludmila HYNKOVÁ; Kateřina POLÁCHOVÁ; Jiri VASINA; Regina DEMLOVÁ; Alexandr POPRACH; Jiří ŠÁNA; Tomáš PROCHÁZKA; Martin SMRČKA; Pavel FADRUS; Radim JANČÁLEK; Iveta SELINGEROVÁ; Renata BELANOVA; Pavel ŠLAMPA; Petr POSPÍŠIL a Tomáš KAZDA. 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET). BMC Cancer. LONDON: BMC, 2024, roč. 24, č. 1, s. 1-16. ISSN 1471-2407. Dostupné z: https://doi.org/10.1186/s12885-024-12469-2.

@article{2418638,
   author = {Lakomý, Radek and Lojová, Martina and Součková, Lenka and Hynková, Ludmila and Poláchová, Kateřina and Vasina, Jiri and Demlová, Regina and Poprach, Alexandr and Šána, Jiří and Procházka, Tomáš and Smrčka, Martin and Fadrus, Pavel and Jančálek, Radim and Selingerová, Iveta and Belanova, Renata and Šlampa, Pavel and Pospíšil, Petr and Kazda, Tomáš},
   article_location = {LONDON},
   article_number = {1},
   doi = {https://doi.org/10.1186/s12885-024-12469-2},
   keywords = {Glioblastoma; Rapid early progression; Radiopharmaceutical; C-11-methionine; Clinical trial; Positron emission tomography; Radiotherapy},
   language = {eng},
   issn = {1471-2407},
   journal = {BMC Cancer},
   title = {11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)},
   url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12469-2},
   volume = {24},
   year = {2024}
}

TY  - JOUR
ID  - 2418638
AU  - Lakomý, Radek - Lojová, Martina - Součková, Lenka - Hynková, Ludmila - Poláchová, Kateřina - Vasina, Jiri - Demlová, Regina - Poprach, Alexandr - Šána, Jiří - Procházka, Tomáš - Smrčka, Martin - Fadrus, Pavel - Jančálek, Radim - Selingerová, Iveta - Belanova, Renata - Šlampa, Pavel - Pospíšil, Petr - Kazda, Tomáš
PY  - 2024
TI  - 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET)
JF  - BMC Cancer
VL  - 24
IS  - 1
SP  - 1-16
EP  - 1-16
PB  - BMC
SN  - 14712407
KW  - Glioblastoma
KW  - Rapid early progression
KW  - Radiopharmaceutical
KW  - C-11-methionine
KW  - Clinical trial
KW  - Positron emission tomography
KW  - Radiotherapy
UR  - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-024-12469-2
N2  - Background Glioblastoma (GBM) is the most common and aggressive primary brain cancer. The treatment of GBM consists of a combination of surgery and subsequent oncological therapy, i.e., radiotherapy, chemotherapy, or their combination. If postoperative oncological therapy involves irradiation, magnetic resonance imaging (MRI) is used for radiotherapy treatment planning. Unfortunately, in some cases, a very early worsening (progression) or return (recurrence) of the disease is observed several weeks after the surgery and is called rapid early progression (REP). Radiotherapy planning is currently based on MRI for target volumes definitions in many radiotherapy facilities. However, patients with REP may benefit from targeting radiotherapy with other imaging modalities. The purpose of the presented clinical trial is to evaluate the utility of C-11-methionine in optimizing radiotherapy for glioblastoma patients with REP. Methods This study is a nonrandomized, open-label, parallel-setting, prospective, monocentric clinical trial. The main aim of this study was to refine the diagnosis in patients with GBM with REP and to optimize subsequent radiotherapy planning. Glioblastoma patients who develop REP within approximately 6 weeks after surgery will undergo C-11-methionine positron emission tomography (PET/CT) examinations. Target volumes for radiotherapy are defined using both standard planning T1-weighted contrast-enhanced MRI and PET/CT. The primary outcome is progression-free survival defined using RANO criteria and compared to a historical cohort with REP treated without PET/CT optimization of radiotherapy. Discussion PET is one of the most modern methods of molecular imaging. C-11-Methionine is an example of a radiolabelled (carbon 11) amino acid commonly used in the diagnosis of brain tumors and in the evaluation of response to treatment. Optimized radiotherapy may also have the potential to cover those regions with a high risk of subsequent progression, which would not be identified using standard-of-care MRI for radiotherapy planning. This is one of the first study focused on radiotherapy optimization for subgroup of patinets with REP.
ER  -

LAKOMÝ, Radek; Martina LOJOVÁ; Lenka SOUČKOVÁ; Ludmila HYNKOVÁ; Kateřina POLÁCHOVÁ; Jiri VASINA; Regina DEMLOVÁ; Alexandr POPRACH; Jiří ŠÁNA; Tomáš PROCHÁZKA; Martin SMRČKA; Pavel FADRUS; Radim JANČÁLEK; Iveta SELINGEROVÁ; Renata BELANOVA; Pavel ŠLAMPA; Petr POSPÍŠIL a Tomáš KAZDA. 11C-methionine in the diagnostics and management of glioblastoma patients with rapid early progression: nonrandomized, open label, prospective clinical trial (GlioMET). \textit{BMC Cancer}. LONDON: BMC, 2024, roč.~24, č.~1, s.~1-16. ISSN~1471-2407. Dostupné z: https://doi.org/10.1186/s12885-024-12469-2.

Přehled o publikaci